News

FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...
Fierce Biotech3d
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
Clinical Trials Arena on MSN1d
Gilead hit with FDA clinical hold for batch of HIV trials
Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
MPR1d
FDA Puts Clinical Hold on Gilead’s Trials for Two HIV Drug Candidates
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
BioSpace3d
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Gilead faces clinical hold on trials of two HIV candidates
The U.S. FDA has placed a clinical hold on trials evaluating Gilead Sciences' GS-1720 and GS-4182, experimental therapies for ...
Why Gilead Scinces Stock Tumbled on Tuesday
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...
Medical Dialogues2d
USFDA places clinical hold on Gilead Sciences trials testing HIV pill combination
Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...
Morningstar3d
Gilead: FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182
Gilead Sciences said the U.S. Food and Drug Administration has placed a clinical hold on studies of an investigational weekly HIV pill combination over signs of potentially weakened immune systems ...
The Motley Fool2d
Why Gilead Scinces Stock Tumbled on Tuesday
The regulator ordered the company to pause its current trials of the pair, GS-1720 and GS-4182, after some participants were found to have low levels of CD4+ T-cells (a type of white blood cell).